bs_bs_banner
Journal of Diabetes (2013) –
R E V I E W A RT I C L E
Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: Consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology Xin GAO,1 and Jian-Gao FAN2 for the Study Group of Liver and Metabolism, Chinese Society of Endocrinology 1 Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University and 2Department of Gastroenterology, Xinhua Hospital, Shanghai, China
Correspondence Xin Gao, Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Shanghai 200032, China. Tel:+86 21 6404 1990 8021 Fax:+86 21 6403 7269 Email: gao.xin@zs-hospital.sh.cn Received 25 July 2012; revised 17 March 2013; accepted 3 April 2013. doi: 10.1111/1753-0407.12056
Abstract Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries, affecting 20%–33% of the general population. Large population-based surveys in China indicate a prevalence of approximately 15%–30%. Worldwide, including in China, the prevalence of NAFLD has increased rapidly in parallel with regional trends of obesity, type2 diabetes and metabolic syndrome. In addition, NAFLD has contributed signi cantly to increased overall, as well as cardiovascular and liver-related, mortality in the general population. In view of rapid advances in research into NAFLD in recent years, this consensus statement provides a brief update on the progress in the eld and suggests preferred approaches for the comprehensive management of NAFLD and its related metabolic diseases. Keywords: NAFLD, metabolic disorders, diagnosis, management.
Introduction Non-alcoholic fatty liver disease (NAFLD) is de ned as liver fat accumulation exceeding 5% by weight that is not the result of excessive alcohol consumption, drugs, toxins, infectious diseases or any other identi able causes. It is a spectrum of disorders ranging from simple fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH) with or without brosis/cirrhosis.1 Even a small proportion of NAFLD patients can advance to hepatocellular carcinoma (HCC). Histologically, NAFL is de ned as the presence of hepatic steatosis with no evidence of hepatocellular injury (e.g. the form of ballooning hepatocytes), whereas NASH is de ned as the presence of hepatic steatosis and in ammation with hepatocyte injury, with or without brosis. In Western countries, NAFLD is the most common liver disorder, affecting 20%–33% of the general population.2,3 In patients with obesity and diabetes, the prevalence of NAFLD is 57.5%–74.0% and 21–78%,
respectively.4 There is strong evidence that the prevalence of NAFLD has been increasing rapidly in the Asia Paci c region in recent years, approaching levels seen in Western countries.5 In China, the prevalence of NAFLD is also of concern. The prevalence of NAFLD has b
een found to be approximately 15% in Shanghai6 and nearly 30% in Hong Kong, as determined by accurate proton magnetic resonance spectroscopy.7 The risk factors for NAFLD include changes in lifestyle, notably the adoption of a high-fat diet and physical inactivity, and the presence of metabolic syndrome or its components, including central abdominal obesity, hypertension, dyslipidemia and type 2 diabetes (T2D).8 It is likely that NAFLD is the hepatic manifestation of metabolic syndrome where insulin resistance is the main risk factor.2 Many recent studies have reported that the increase in the prevalence of NAFLD is associated with increases in the prevalence of prediabetes, diabetes, and cardiovascular disease.9,10 There is also evidence that the prevalence of NAFLD prevalence is affected by age,
© 2013 The Authors. Journal of Diabetes published by Wiley Publishing Asia Pty Ltd and Ruijin Hospital, Shanghai Jiaotong University School of Medicine. 1 This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

between non-alcoholic fatty liver disease and celiac disease Ludovico ...et al., Is coeliac disease a confounding factor in the diagnosis of NASH...
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver...
指南 Brief introduction of practice guideline for the diagnosis and management of non-alcoholic fatty liver disease SHEN Feng, DING Xiao-Dong, FAN Jian-...
1 TOP 10:美国非酒精性脂肪性肝病诊治指南 非酒精性脂肪肝病是慢性肝病的常见类型 The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice ...
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the american association for the study of liver diseases, American...
Weight reduction for non-alcoholic fatty liver disease CD003619_医药卫生_专业...Ultrasonography and liver enzyme levels at diagnosis and during follow-up in...
NASH was the most common diagnosis in patients presenting largely with persistent...ned to patients with non-alcoholic fatty liver only.11 Further evidence ...
Fatty Liver Vishnudutt Purohit1,*, Bin Gao2, and Byoung-Joon Song3,* ...Diagnosis and therapy of alcoholic liver disease. Semin Liver Dis. 2004; ...
Spectrum of ALD Alcoholic cirrhosis (39%) Alcoholic fatty liver (27%) ...uidelines for the diagnosis and management of alcoholic liver disease: Update...
Surveillance After Screening and Polypectomy The Diagnosis and Management of Non-alcoholic Fatty Liver Disease Upper Endoscopy for Gastroesophageal Reflux Disease...
热门文档